

CITATION REPORT

List of articles citing

Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation

DOI: 10.1111/jth.14445

Journal of Thrombosis and Haemostasis, 2019, 17, 885-895.

Source: <https://exaly.com/paper-pdf/73625355/citation-report.pdf>

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
33	Measurement of Thromboxane Biosynthesis in Health and Disease. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1244	5.6	23
32	Aspirin in primary prevention: the triumph of clinical judgement over complex equations. <i>Internal and Emergency Medicine</i> , 2019 , 14, 1217-1231	3.7	3
31	Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. <i>Diabetes Research and Clinical Practice</i> , 2020 , 160, 108008	7.4	10
30	Effect of Low-dose and Standard-dose Aspirin on PGE Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial. <i>Cancer Prevention Research</i> , 2020 , 13, 877-888	3.2	12
29	Patients with Essential Thrombocythemia may be Poor Responders to Enteric-Coated Aspirin, but not to Plain Aspirin. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1442-1453	7	10
28	Venous thromboembolism prophylaxis in patients undergoing knee replacements: comparison of real-world outcomes. <i>International Journal of Clinical Pharmacy</i> , 2021 , 43, 621-628	2.3	3
27	Phosphoproteomic Analysis of Platelets in Severe Obesity Uncovers Platelet Reactivity and Signaling Pathways Alterations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, 478-490	9.4	2
26	Aspirin in the Prevention of Colorectal Neoplasia. <i>Annual Review of Medicine</i> , 2021 , 72, 415-430	17.4	12
25	Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity. <i>Vascular Pharmacology</i> , 2021 , 136, 106819	5.9	1
24	The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. <i>Cardiovascular Research</i> , 2021 , 117, 2001-2015	9.9	9
23	Aspirin Resistance in Obese and Elderly Patients with COVID-19?. <i>American Journal of Medicine</i> , 2021 , 134, e297	2.4	
22	Pharmacotherapy of obesity: An update. <i>Pharmacological Research</i> , 2021 , 169, 105649	10.2	7
21	Transcriptome-wide Effects of Aspirin on Patient-derived Normal Colon Organoids. <i>Cancer Prevention Research</i> , 2021 , 14, 1089-1100	3.2	3
20	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. <i>Blood</i> , 2020 , 136, 171-182	2.2	33
19	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. <i>Ecancermedicalscience</i> , 2020 , 14, 998	2.7	2
18	Primary prevention of cardiovascular diseases in diabetes mellitus: 2020 strategy. <i>Meditinskiy Sovet</i> , 2020 , 42-49	0.4	
17	Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy. <i>Thrombosis Research</i> , 2021 , 208, 92-98	8.2	0

16	Are Aspirin and Apixaban Sufficient to Prevent Immunothrombosis in COVID-19?. <i>SSRN Electronic Journal</i> ,	1	0
15	Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. <i>Current Opinion in Nephrology and Hypertension</i> , 2022 , 31, 36-46	3.5	2
14	Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath.. <i>Expert Opinion on Therapeutic Targets</i> , 2022 ,	6.4	2
13	Updates on Clinical Trials in Diagnosis and Therapy of Colorectal Cancer. 2022 , 1-19		
12	Antithrombotic effect of different acetylsalicylic acid drug formulations: is there a difference?. <i>Russian Journal of Cardiology</i> , 2021 , 26, 4734	1.3	1
11	Platelet inhibition by low-dose aspirin is not influenced by body mass or weight. <i>Platelets</i> , 1-6	3.6	1
10	Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022 , 6,	5.1	0
9	Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases. <i>Antioxidants</i> , 2022 , 11, 14087.1	7.1	2
8	Physiologically based modelling of the antiplatelet effect of aspirin: A tool to characterize drug responsiveness and inform precision dosing. 2022 , 17, e0268905		
7	The biological actions of prostanoids in adipose tissue in physiological and pathophysiological conditions. 2022 , 102508		0
6	Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation.		0
5	An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention. 2023 , 63,		1
4	Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin. 2023 , 11, 338		0
3	Implementing an innovative, patient-centered approach to day case arthroplasty: improving patient outcomes through remote preoperative pharmacist consultations. ejhpharm-2022-003573		0
2	Prospective, randomized, controlled, trial to assess ASA DOS ing by body mass index in H E althy volunteers (DOSE study). 2023 , 43, 215-225		0
1	Myopenic Obesity Determined by Fat Mass Percentage Predicts Risk of Aspirin-Induced Bleeding in Chinese Older Adults. Volume 18, 585-595		0